Expanded and Independent Spanish Validation of the MDS-Non Motor Rating Scale

and the Spanish MDS-NMS Validation Study Group

doi:10.1002/mdc3.13658

Expanded and Independent Spanish Validation of the MDS-Non Motor Rating Scale

and the Spanish MDS-NMS Validation Study Group

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS) assess the severity and disability caused by non-motor symptoms (NMS) in Parkinson's disease (PD). This article encapsulates the formal process for completing this program and the data on the first officially approved non-English version of the MDS-NMS (Spanish). The MDS-NMS translation program involves four steps: translation and back-translation; cognitive pre-testing to ensure that raters and patients understand the scale and are comfortable with its content; field testing of the finalized version; analysis of the factor structure of the tested version against the original English language version for the nine domains that could be analyzed in a confirmatory factor analysis. To be designated an “Official MDS translation,” the confirmatory factor analysis Comparative Fit Index had to be ≥0.90. The Spanish MDS-NMS was tested in 364 native-Spanish-speaking patients with PD from seven countries. For all subjects with fully computable data with all domains of the MDS-NMS (n = 349), the Comparative Fit Index was ≥0.90 for the nine eligible domains. Missing data were negligible and moderate floor effect (42.90%) was found for the Non-Motor Fluctuations subscale. Item homogeneity coefficient was adequate, and the correlation of the MDS-NMS domains with other measures for related constructs was acceptable (rs ≥ 0.50). The Spanish version of the MDS-NMS followed the IPMDS Translation Program protocol, reached the criterion to be designated as an Official Translation, and is now available on the MDS website.

Original language	English
Pages (from-to)	586-595
Number of pages	10
Journal	Movement Disorders Clinical Practice
Volume	10
Issue number	4
DOIs	https://doi.org/10.1002/mdc3.13658
State	Published - Apr 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Funding

The authors acknowledge grant support from the International Parkinson and Movement Disorder Society to plan, develop, and validate the Spanish version of the MDS-NMS in an international study. P.M.: has received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Allergan, Abbvie. Bial, Britannia, Italfarmaco, Merz, UCB, Teva and Zambon and has received grants from Spanish Ministry of Science and Innovation [RTC2019‐007150‐ 1], the Instituto de Salud Carlos III‐Fondo Europeo de Desarrollo Regional (ISCIII‐FEDER) [PI19/01576], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [PE‐0210‐2018] and the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía [PY20_00903]. C.S.: has received grants from Sunovion, Revance, Pharma2B, Amneal and Adamas. He has received honoraria from the Movement Disorders Society. D.S.G.: has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, Italfarmaco, Teva, Archímedes, Esteve, Stada, Merz, and grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co‐founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017–2020 por el proyecto “PROGRESIÓN NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”). The authors acknowledge grant support from the International Parkinson and Movement Disorder Society to plan, develop, and validate the Spanish version of the MDS‐NMS in an international study. G.T.S.: received honoraria for consulting and advisory board membership with Acadia Pharmaceuticals, Adamas Pharmaceuticals Inc., Biogen Inc., Ceregene Inc., CHDI Management Inc., Cleveland Clinic Foundation, Ingenix Pharmaceutical Services (i3 Research), MedGenesis Therapeutix Inc., Neurocrine Biosciences Inc., Pfizer Inc., Tools‐4‐Patients, Ultragenyx Inc., and Sunshine Care Foundation. He also received honoraria from the International Parkinson and Movement Disorder Society, American Academy of Neurology, Michael J. Fox Foundation for Parkinson's Research, Food and Drug Administration, National Institutes of Health, Alzheimer's Association. He also received grants and research from National Institutes of Health, Department of Defense, Michael J. Fox Foundation for Parkinson's Research, Dystonia Coalition, CHDI, Cleveland Clinic Foundation, International Parkinson and Movement Disorder Society, CBD Solution. E.C.: has received honoraria for educational presentations and advice service by Abbvie, Italfarmaco and grants from the Spanish Ministry of Economy and Competitiveness [PI19/0964], the Fundación “la Caixa” and Fundación “Caja de Burgos” (Course 2019/2020), Horizon 2020: Multi‐Domain Lifestyle Targets for Improving ProgNOsis in Huntington's Disease. DOMINO‐HD. Horizon 2020. Financial Disclosures for Previous 12 Months:

Funders	Funder number
Amneal and Adamas
ISCIII‐FEDER	PI19/01576
Instituto de Salud Carlos III‐Fondo Europeo de Desarrollo Regional
MDS-NMS
National Institutes of Health
U.S. Department of Defense
CHDI Foundation
Teva Pharmaceutical Industries
AbbVie
Cleveland Clinic Foundation
International Parkinson and Movement Disorder Society
Sunovion
“la Caixa” Foundation
UCB
Consejería de Transformación Económica, Industria, Conocimiento y Universidades	PY20_00903
Ministerio de Economía y Competitividad	PI16/01575, PI19/0964
Instituto de Salud Carlos III
Ministerio de Ciencia e Innovación	RTC2019‐007150‐ 1
Horizon 2020
Consejería de Salud y Familias, Junta de Andalucía	PE‐0210‐2018

Keywords

non-motor symptoms
Parkinson's disease
rating scale

Access to Document

10.1002/mdc3.13658

Cite this

@article{1ee330b8e22041ca870711bc90a9cecd,

title = "Expanded and Independent Spanish Validation of the MDS-Non Motor Rating Scale",

abstract = "The Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS) assess the severity and disability caused by non-motor symptoms (NMS) in Parkinson's disease (PD). This article encapsulates the formal process for completing this program and the data on the first officially approved non-English version of the MDS-NMS (Spanish). The MDS-NMS translation program involves four steps: translation and back-translation; cognitive pre-testing to ensure that raters and patients understand the scale and are comfortable with its content; field testing of the finalized version; analysis of the factor structure of the tested version against the original English language version for the nine domains that could be analyzed in a confirmatory factor analysis. To be designated an “Official MDS translation,” the confirmatory factor analysis Comparative Fit Index had to be ≥0.90. The Spanish MDS-NMS was tested in 364 native-Spanish-speaking patients with PD from seven countries. For all subjects with fully computable data with all domains of the MDS-NMS (n = 349), the Comparative Fit Index was ≥0.90 for the nine eligible domains. Missing data were negligible and moderate floor effect (42.90%) was found for the Non-Motor Fluctuations subscale. Item homogeneity coefficient was adequate, and the correlation of the MDS-NMS domains with other measures for related constructs was acceptable (rs ≥ 0.50). The Spanish version of the MDS-NMS followed the IPMDS Translation Program protocol, reached the criterion to be designated as an Official Translation, and is now available on the MDS website.",

keywords = "non-motor symptoms, Parkinson's disease, rating scale",

author = "{and the Spanish MDS-NMS Validation Study Group} and Esther Cubo and Sheng Luo and Pablo Mart{\'i}nez-Mart{\'i}n and Stebbins, {Glenn T.} and Jeffrey Lin and Dongrak Choi and Alvaro Garc{\'i}a-Bustillo and Pablo Mir and Diego Santos-Garcia and Marcos Serrano-Due{\~n}as and Mayela Rodriguez-Violante and Carlos Singer and Fern{\'a}ndez, {Carmen Borrue} and Alvarez-Santullano, {Marina Mata} and Iria Cabo and Ram{\'i}rez, {In{\'e}s Legarda} and Garc{\'i}a, {Mar{\'i}a Fuensanta Valero} and Pastor, {B{\'a}rbara Vives} and Anna Planas and Pons, {Nuria Caballol} and Asunci{\'o}n {\'A}vila and Ariztegui, {Nuria L{\'o}pez} and Casado, {Mª Isabel Morales} and Pe{\~n}a, {Mar Sierra} and Pel{\'a}ez, {Mar{\'i}a Victoria S{\'a}nchez} and Arroyo, {Sonia Escalante} and Lezama, {Lidia Binela Lara} and Sauco, {Mar{\'i}a {\'A}lvarez} and Pajar{\'i}n, {Gustavo Fern{\'a}ndez} and Frech, {Fernando Alonso} and Mayordomo, {V{\'i}ctor G{\'o}mez} and Ferro, {{\'A}lvaro S{\'a}nchez} and Fern{\'a}ndez, {David Seoane} and Salas, {Carmen Gasca} and Elena and Natera Villalba and Dra Samaniego-Toro and Jorge Hern{\'a}ndez-Vara and Nelida Garretto and Tomoko Arakaki and Henry Moore and Ingrid Estrada-Bellmann and Ivonne Pedroso and Oscar Bernal",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.",

year = "2023",

month = apr,

doi = "10.1002/mdc3.13658",

language = "English",

volume = "10",

pages = "586--595",

journal = "Movement Disorders Clinical Practice",

issn = "2330-1619",

publisher = "John Wiley and Sons Ltd",

number = "4",

}

TY - JOUR

T1 - Expanded and Independent Spanish Validation of the MDS-Non Motor Rating Scale

AU - and the Spanish MDS-NMS Validation Study Group

AU - Cubo, Esther

AU - Luo, Sheng

AU - Martínez-Martín, Pablo

AU - Stebbins, Glenn T.

AU - Lin, Jeffrey

AU - Choi, Dongrak

AU - García-Bustillo, Alvaro

AU - Mir, Pablo

AU - Santos-Garcia, Diego

AU - Serrano-Dueñas, Marcos

AU - Rodriguez-Violante, Mayela

AU - Singer, Carlos

AU - Fernández, Carmen Borrue

AU - Alvarez-Santullano, Marina Mata

AU - Cabo, Iria

AU - Ramírez, Inés Legarda

AU - García, María Fuensanta Valero

AU - Pastor, Bárbara Vives

AU - Planas, Anna

AU - Pons, Nuria Caballol

AU - Ávila, Asunción

AU - Ariztegui, Nuria López

AU - Casado, Mª Isabel Morales

AU - Peña, Mar Sierra

AU - Peláez, María Victoria Sánchez

AU - Arroyo, Sonia Escalante

AU - Lezama, Lidia Binela Lara

AU - Sauco, María Álvarez

AU - Pajarín, Gustavo Fernández

AU - Frech, Fernando Alonso

AU - Mayordomo, Víctor Gómez

AU - Ferro, Álvaro Sánchez

AU - Fernández, David Seoane

AU - Salas, Carmen Gasca

AU - Elena,

AU - Villalba, Natera

AU - Samaniego-Toro, Dra

AU - Hernández-Vara, Jorge

AU - Garretto, Nelida

AU - Arakaki, Tomoko

AU - Moore, Henry

AU - Estrada-Bellmann, Ingrid

AU - Pedroso, Ivonne

AU - Bernal, Oscar

PY - 2023/4

Y1 - 2023/4

N2 - The Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS) assess the severity and disability caused by non-motor symptoms (NMS) in Parkinson's disease (PD). This article encapsulates the formal process for completing this program and the data on the first officially approved non-English version of the MDS-NMS (Spanish). The MDS-NMS translation program involves four steps: translation and back-translation; cognitive pre-testing to ensure that raters and patients understand the scale and are comfortable with its content; field testing of the finalized version; analysis of the factor structure of the tested version against the original English language version for the nine domains that could be analyzed in a confirmatory factor analysis. To be designated an “Official MDS translation,” the confirmatory factor analysis Comparative Fit Index had to be ≥0.90. The Spanish MDS-NMS was tested in 364 native-Spanish-speaking patients with PD from seven countries. For all subjects with fully computable data with all domains of the MDS-NMS (n = 349), the Comparative Fit Index was ≥0.90 for the nine eligible domains. Missing data were negligible and moderate floor effect (42.90%) was found for the Non-Motor Fluctuations subscale. Item homogeneity coefficient was adequate, and the correlation of the MDS-NMS domains with other measures for related constructs was acceptable (rs ≥ 0.50). The Spanish version of the MDS-NMS followed the IPMDS Translation Program protocol, reached the criterion to be designated as an Official Translation, and is now available on the MDS website.

AB - The Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS) assess the severity and disability caused by non-motor symptoms (NMS) in Parkinson's disease (PD). This article encapsulates the formal process for completing this program and the data on the first officially approved non-English version of the MDS-NMS (Spanish). The MDS-NMS translation program involves four steps: translation and back-translation; cognitive pre-testing to ensure that raters and patients understand the scale and are comfortable with its content; field testing of the finalized version; analysis of the factor structure of the tested version against the original English language version for the nine domains that could be analyzed in a confirmatory factor analysis. To be designated an “Official MDS translation,” the confirmatory factor analysis Comparative Fit Index had to be ≥0.90. The Spanish MDS-NMS was tested in 364 native-Spanish-speaking patients with PD from seven countries. For all subjects with fully computable data with all domains of the MDS-NMS (n = 349), the Comparative Fit Index was ≥0.90 for the nine eligible domains. Missing data were negligible and moderate floor effect (42.90%) was found for the Non-Motor Fluctuations subscale. Item homogeneity coefficient was adequate, and the correlation of the MDS-NMS domains with other measures for related constructs was acceptable (rs ≥ 0.50). The Spanish version of the MDS-NMS followed the IPMDS Translation Program protocol, reached the criterion to be designated as an Official Translation, and is now available on the MDS website.

KW - non-motor symptoms

KW - Parkinson's disease

KW - rating scale

UR - http://www.scopus.com/inward/record.url?scp=85150639425&partnerID=8YFLogxK

U2 - 10.1002/mdc3.13658

DO - 10.1002/mdc3.13658

M3 - Article

SN - 2330-1619

VL - 10

SP - 586

EP - 595

JO - Movement Disorders Clinical Practice

JF - Movement Disorders Clinical Practice

IS - 4

ER -

Expanded and Independent Spanish Validation of the MDS-Non Motor Rating Scale

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this